TÀI LIỆU THAM KHẢO
1. Muñoz N et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348(6):518-27, 2003
2. Meites E et al; for CDC: Human Papillomavirus. In: Hall E et al, eds: Pink Book: Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Public Health Foundation; 2021:chap 11
3. Bruggink SC et al: Cutaneous wart-associated HPV types: prevalence and relation with patient characteristics. J Clin Virol. 55(3):250-5, 2012
4. Lynch MD et al: Management of cutaneous viral warts. BMJ. 348:g3339, 2014
5. ACOG: Practice Advisory: Updated Cervical Cancer Screening Guidelines. Published April 2021. Reaffirmed April 2023. Accessed January 13, 2024. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines
6. Meites E et al: Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 68(32):698-702, 2019
7. Workowski KA et al: Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 70(4):1-187, 2021
8. Mulhem E et al: Treatment of nongenital cutaneous warts. Am Fam Physician. 84(3):288-93, 2011
9. Bacelieri R et al: Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician. 72(4):647-52, 2005
10. Lipke MM: An armamentarium of wart treatments. Clin Med Res. 4(4):273-93, 2006
11. Yanofsky VR et al: Genital warts: a comprehensive review. J Clin Aesthet Dermatol. 5(6):25-36, 2012
12. Oriel JD: Natural history of genital warts. Br J Vener Dis. 47(1):1-13, 1971
13. Chelimo C et al: Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect. 66(3):207-17, 2013
14. Senkomago V et al: Human papillomavirus-attributable cancers – United States, 2012-2016. MMWR Morb Mortal Wkly Rep. 68(33):724-8, 2019
15. Loo SK et al: Warts (non-genital). BMJ Clin Evid. 2009:1710, 2009
16. Quinlan JD: Human papillomavirus: screening, testing, and pPrevention. Am Fam Physician. 104(2):152-9, 2021
17. Homfray V et al: Male circumcision and STI acquisition in Britain: evidence from a national probability sample survey. PLoS One. 10(6):e0130396, 2015
18. ACOG: Practice Advisory: Updated Guidelines for Management of Cervical Cancer Screening Abnormalities. Published October 2020. Reaffirmed October 2023. Accessed January 13, 2024. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/10/updated-guidelines-for-management-of-cervical-cancer-screening-abnormalities
19. Schiffman M et al: An introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 24(2):87-9, 2020
20. Perkins RB et al: 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 24(2):102-31, 2020
21. National Cancer Institute: Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. NIH website. Accessed January 13, 2024. https://cervixca.nlm.nih.gov/RiskTables/
22. Nayar R et al: The Pap test and Bethesda 2014. Cancer Cytopathol. 123(5):271-81, 2015
23. Nayar R et al, eds: The Bethesda System for Reporting Cervical Cytology. Definitions, Criteria, and Explanatory Notes. 3rd ed. Springer; 2015
24. Jhingran A et al: Cancers of the cervix, vulva, and vagina. In: Niederhuber JE et al, eds: Abeloff’s Clinical Oncology. 5th ed. Elsevier; 2014:1534-74.e8
25. Darragh TM et al: The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 32(1):76-115, 2013
26. Waxman AG et al: Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol. 120(6):1465-71, 2012
27. Rosen T et al: Cutaneous manifestations of sexually transmitted diseases. Med Clin North Am. 82(5):1081-104, vi, 1998
28. Sterling JC et al: British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014. Br J Dermatol. 171(4):696-712, 2014
29. McLaughlin JS et al: Cutaneous warts. J Hand Surg Am. 36(2):343-4, 2011
30. Goldman RD: Duct tape for warts in children: Should nature take its course? Can Fam Physician. 65(5):337-8, 2019
31. Dall’oglio F et al: Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol. 13(2):73-96, 2012
32. Miller DJ et al: Management of cutaneous warts of the hand. J Hand Surg Am. 40(11):2274-6, 2015
33. Nguyen J et al: Laser treatment of nongenital verrucae: a systematic review. JAMA Dermatol. 152(9):1025-34, 2016
34. Vlahovic TC et al: The human papillomavirus and its role in plantar warts: a comprehensive review of diagnosis and management. Clin Podiatr Med Surg. 33(3):337-53, 2016
35. Gilson R et al: 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 34(8):1644-53, 2020
36. Perkins RB et al: Summary of current guidelines for cervical cancer screening and management of abnormal test results: 2016-2020. J Womens Health (Larchmt). 30(1):5-13, 2021
37. Knight KL: Cryotherapy Theory: Technique and Physiology. Chattanooga Corporation; 1985
38. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, The National Institutes of Health, and the HIV Medicine Association of America. Human papillomavirus infection. Updated July 9, 2024. Reviewed July 9, 2024. Accessed February 12. 2025. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/human-papillomavirus-disease
39. Efudex (fluorouracil) topical solutions and cream. Package insert. Bausch Health US, LLC; 2021
40. American Academy of Pediatrics: Human papillomaviruses. In: Kimberlin DW et al, eds: Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021:440-7
41. American Association of Oral and Maxillofacial Surgeons. Human papillomavirus vaccination. 2020. Accessed January 13, 2024. https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/HPV-vaccination_PositionPaper.pdf
42. Elfgren K et al: Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. Am J Obstet Gynecol. ePub, 2016
43. US Preventive Services Task Force: Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 20(7):674-86, 2018
44. Zhang S et al: Human papillomavirus in 2019: an update on cervical cancer prevention and screening guidelines. Cleve Clin J Med. 86(3):173-8, 2019
45. Gilham C et al: HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Health Technol Assess. 23(28):1-44, 2019
46. Fontham ETH et al: Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 70(5):321-46, 2020
47. Kim SC et al: Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology (Oxford). 57(suppl_5):v26-v33, 2018
48. Moscicki AB et al: Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 23(2):87-101, 2019
49. Rayner M et al: Cervical cancer screening recommendations: now and for the future. Healthcare (Basel). 11(16):2273, 2023
50. New York State Department of Health AIDS Institute: Screening for Anal Dysplasia and Cancer in Patients with HIV. HIV guidelines website. Updated August 9, 2022. Accessed January 13, 2024. https://www.hivguidelines.org/guideline/hiv-anal-cancer/?mycollection=hpv-care
51. Arbyn M et al: Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 5:CD009069, 2018
52. Porras C et al: Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncol. 21(12):1643-52, 2020
53. Garland SM et al: Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. ePub, 2016
54. Lowy DR: HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest. 126(1):5-11, 2016
55. Naleway AL et al: Temporal trends in the incidence of anogenital warts: impact of human papillomavirus vaccination. Sex Transm Dis. 47(3):179-86, 2020
56. Ponduri A et al: The efficacy of human papillomavirus vaccination as an adjuvant therapy in recurrent respiratory papillomatosis. Laryngoscope. 133(9):2046-54, 2023
57. Bergman H et al: Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019(11), 2019
58. Saslow D et al: Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. ePub, 2020
59. Human papillomavirus vaccination: ACOG Committee Opinion, Number 809. Obstet Gynecol. 136(2):e15-e21, 2020
60. Bednarczyk RA et al: Human papillomavirus vaccination at the first opportunity: an overview. Hum Vaccin Immunother. 19(1):2213603, 2023
61. Arrossi S et al: Primary prevention of cervical cancer: American Society of Clinical Oncology resource-stratified guideline. J Glob Oncol. 3(5):611-34, 2017
62. CDC: Human Papillomavirus (HPV): HPV Vaccine Schedule and Dosing. CDC website. Reviewed: July 9, 2024. Accessed January 24, 2025. https://www.cdc.gov/hpv/hcp/schedules-recommendations.html
63. Ellingson MK et al: Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review. Hum Vaccin Immunother. 19(2):2239085, 2023
64. World Health Organization: Human papillomavirus vaccines: WHO position paper (2022 update). Weekly Epidemiological Record. 50(97):645–72, 2022
65. Goldstone SE: Human papillomavirus (HPV) vaccines in adults: learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials. Hum Vaccin Immunother. 19(1):2184760, 2023
2. Meites E et al; for CDC: Human Papillomavirus. In: Hall E et al, eds: Pink Book: Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Public Health Foundation; 2021:chap 11
3. Bruggink SC et al: Cutaneous wart-associated HPV types: prevalence and relation with patient characteristics. J Clin Virol. 55(3):250-5, 2012
4. Lynch MD et al: Management of cutaneous viral warts. BMJ. 348:g3339, 2014
5. ACOG: Practice Advisory: Updated Cervical Cancer Screening Guidelines. Published April 2021. Reaffirmed April 2023. Accessed January 13, 2024. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines
6. Meites E et al: Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 68(32):698-702, 2019
7. Workowski KA et al: Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 70(4):1-187, 2021
8. Mulhem E et al: Treatment of nongenital cutaneous warts. Am Fam Physician. 84(3):288-93, 2011
9. Bacelieri R et al: Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician. 72(4):647-52, 2005
10. Lipke MM: An armamentarium of wart treatments. Clin Med Res. 4(4):273-93, 2006
11. Yanofsky VR et al: Genital warts: a comprehensive review. J Clin Aesthet Dermatol. 5(6):25-36, 2012
12. Oriel JD: Natural history of genital warts. Br J Vener Dis. 47(1):1-13, 1971
13. Chelimo C et al: Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect. 66(3):207-17, 2013
14. Senkomago V et al: Human papillomavirus-attributable cancers – United States, 2012-2016. MMWR Morb Mortal Wkly Rep. 68(33):724-8, 2019
15. Loo SK et al: Warts (non-genital). BMJ Clin Evid. 2009:1710, 2009
16. Quinlan JD: Human papillomavirus: screening, testing, and pPrevention. Am Fam Physician. 104(2):152-9, 2021
17. Homfray V et al: Male circumcision and STI acquisition in Britain: evidence from a national probability sample survey. PLoS One. 10(6):e0130396, 2015
18. ACOG: Practice Advisory: Updated Guidelines for Management of Cervical Cancer Screening Abnormalities. Published October 2020. Reaffirmed October 2023. Accessed January 13, 2024. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/10/updated-guidelines-for-management-of-cervical-cancer-screening-abnormalities
19. Schiffman M et al: An introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 24(2):87-9, 2020
20. Perkins RB et al: 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 24(2):102-31, 2020
21. National Cancer Institute: Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. NIH website. Accessed January 13, 2024. https://cervixca.nlm.nih.gov/RiskTables/
22. Nayar R et al: The Pap test and Bethesda 2014. Cancer Cytopathol. 123(5):271-81, 2015
23. Nayar R et al, eds: The Bethesda System for Reporting Cervical Cytology. Definitions, Criteria, and Explanatory Notes. 3rd ed. Springer; 2015
24. Jhingran A et al: Cancers of the cervix, vulva, and vagina. In: Niederhuber JE et al, eds: Abeloff’s Clinical Oncology. 5th ed. Elsevier; 2014:1534-74.e8
25. Darragh TM et al: The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 32(1):76-115, 2013
26. Waxman AG et al: Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol. 120(6):1465-71, 2012
27. Rosen T et al: Cutaneous manifestations of sexually transmitted diseases. Med Clin North Am. 82(5):1081-104, vi, 1998
28. Sterling JC et al: British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014. Br J Dermatol. 171(4):696-712, 2014
29. McLaughlin JS et al: Cutaneous warts. J Hand Surg Am. 36(2):343-4, 2011
30. Goldman RD: Duct tape for warts in children: Should nature take its course? Can Fam Physician. 65(5):337-8, 2019
31. Dall’oglio F et al: Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol. 13(2):73-96, 2012
32. Miller DJ et al: Management of cutaneous warts of the hand. J Hand Surg Am. 40(11):2274-6, 2015
33. Nguyen J et al: Laser treatment of nongenital verrucae: a systematic review. JAMA Dermatol. 152(9):1025-34, 2016
34. Vlahovic TC et al: The human papillomavirus and its role in plantar warts: a comprehensive review of diagnosis and management. Clin Podiatr Med Surg. 33(3):337-53, 2016
35. Gilson R et al: 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 34(8):1644-53, 2020
36. Perkins RB et al: Summary of current guidelines for cervical cancer screening and management of abnormal test results: 2016-2020. J Womens Health (Larchmt). 30(1):5-13, 2021
37. Knight KL: Cryotherapy Theory: Technique and Physiology. Chattanooga Corporation; 1985
38. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, The National Institutes of Health, and the HIV Medicine Association of America. Human papillomavirus infection. Updated July 9, 2024. Reviewed July 9, 2024. Accessed February 12. 2025. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/human-papillomavirus-disease
39. Efudex (fluorouracil) topical solutions and cream. Package insert. Bausch Health US, LLC; 2021
40. American Academy of Pediatrics: Human papillomaviruses. In: Kimberlin DW et al, eds: Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021:440-7
41. American Association of Oral and Maxillofacial Surgeons. Human papillomavirus vaccination. 2020. Accessed January 13, 2024. https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/HPV-vaccination_PositionPaper.pdf
42. Elfgren K et al: Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. Am J Obstet Gynecol. ePub, 2016
43. US Preventive Services Task Force: Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 20(7):674-86, 2018
44. Zhang S et al: Human papillomavirus in 2019: an update on cervical cancer prevention and screening guidelines. Cleve Clin J Med. 86(3):173-8, 2019
45. Gilham C et al: HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Health Technol Assess. 23(28):1-44, 2019
46. Fontham ETH et al: Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 70(5):321-46, 2020
47. Kim SC et al: Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology (Oxford). 57(suppl_5):v26-v33, 2018
48. Moscicki AB et al: Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 23(2):87-101, 2019
49. Rayner M et al: Cervical cancer screening recommendations: now and for the future. Healthcare (Basel). 11(16):2273, 2023
50. New York State Department of Health AIDS Institute: Screening for Anal Dysplasia and Cancer in Patients with HIV. HIV guidelines website. Updated August 9, 2022. Accessed January 13, 2024. https://www.hivguidelines.org/guideline/hiv-anal-cancer/?mycollection=hpv-care
51. Arbyn M et al: Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 5:CD009069, 2018
52. Porras C et al: Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncol. 21(12):1643-52, 2020
53. Garland SM et al: Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. ePub, 2016
54. Lowy DR: HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest. 126(1):5-11, 2016
55. Naleway AL et al: Temporal trends in the incidence of anogenital warts: impact of human papillomavirus vaccination. Sex Transm Dis. 47(3):179-86, 2020
56. Ponduri A et al: The efficacy of human papillomavirus vaccination as an adjuvant therapy in recurrent respiratory papillomatosis. Laryngoscope. 133(9):2046-54, 2023
57. Bergman H et al: Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019(11), 2019
58. Saslow D et al: Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. ePub, 2020
59. Human papillomavirus vaccination: ACOG Committee Opinion, Number 809. Obstet Gynecol. 136(2):e15-e21, 2020
60. Bednarczyk RA et al: Human papillomavirus vaccination at the first opportunity: an overview. Hum Vaccin Immunother. 19(1):2213603, 2023
61. Arrossi S et al: Primary prevention of cervical cancer: American Society of Clinical Oncology resource-stratified guideline. J Glob Oncol. 3(5):611-34, 2017
62. CDC: Human Papillomavirus (HPV): HPV Vaccine Schedule and Dosing. CDC website. Reviewed: July 9, 2024. Accessed January 24, 2025. https://www.cdc.gov/hpv/hcp/schedules-recommendations.html
63. Ellingson MK et al: Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review. Hum Vaccin Immunother. 19(2):2239085, 2023
64. World Health Organization: Human papillomavirus vaccines: WHO position paper (2022 update). Weekly Epidemiological Record. 50(97):645–72, 2022
65. Goldstone SE: Human papillomavirus (HPV) vaccines in adults: learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials. Hum Vaccin Immunother. 19(1):2184760, 2023
BÌNH LUẬN